OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Gastroenterology & Hepatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	964
Zolbetuximab treatment in metastatic gastric cancer	686
Hybrid EASL Congress 2023	640
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	629
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	553
Mapping neuroimmune interactions in the gut	548
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	497
2023 FDA approvals in gastroenterology and hepatology	490
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	433
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	426
Western lifestyle, metaflammation and the cell of origin of colon cancer	343
Nomenclature of HBV core protein-targeting antivirals	322
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	297
Advancing nutrition science for global health	294
The future of treating pancreatic exocrine insufficiency	271
Digestive Disease Week 2022	266
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health	260
Black–White disparities across the colorectal cancer care continuum in the USA	249
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	238
Large language models for clinical decision support in gastroenterology and hepatology	233
Artificial intelligence and automation in endoscopy and surgery	219
New understanding of hepatobiliary MRI	214
Metastatic pancreatic cancer and the liver	210
Lessons from incretin-based therapy in MASH and obesity	202
Inflammatory bowel disease in pregnancy and breastfeeding	196

A crucial Fusobacterium nucleatum clade in colorectal cancer	195
Novel insights into chronic HBV infection	183
Food as medicine in gastrointestinal cancer therapy	182
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease	179
The critical role of gut–brain signalling in eating behaviour and obesity	173
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	171
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	168
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	168
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	165
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	156
Integrated systems approach to identify environmental factors in intestinal inflammation	155
Characterizing the genomic landscape of colorectal cancer	152
Implications of the evolving knowledge of the genetic architecture of MASLD	152
Estimating dietary intake from human stool DNA	141
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	141
HDCA ameliorates NAFLD in mice	135
Probiotics for preterms: sharing complex decision-making	134
The path to successful hepatitis C elimination in Spain	132
Preventing the progression of cirrhosis to decompensation and death	128
Medical therapy of paediatric inflammatory bowel disease	127
Metabolic diseases in the East Asian populations	124
Human intestinal B cells in inflammatory diseases	119
SSRIs and depression: role of gut–brain communication	113
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	106
Current and future colorectal cancer screening strategies	103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease	99
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	98
Proteases in intestinal health and disease	93
Liver, ageing and disease	91
ECCO’24	88
Phase III results for first-line treatment for metastatic colorectal cancer	88
NAFLD prevalence in older patients with T2DM	88
GLP1R agonists in NAFLD: a promising therapy on the horizon	82
Microbiota and colorectal cancer — controlling for confounders challenges associations	82
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	80
Enteric nervous system transfers stress to the gut	79
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	77
Author Correction: Hepatic immune regulation and sex disparities	71
The future of pathology in gastroenterology and hepatology	69
Transforming the landscape of liver cancer detection and care	65
HIV-associated gut microbiome influences gut mucosal immunity	64
Hepatic glucose metabolism in the steatotic liver	64
Hepatic inflammatory responses in liver fibrosis	64
Artificial intelligence in liver cancer — new tools for research and patient management	62
SMART cancer risk prediction	61
AI predicts pancreatic cancer risk	60
Liver dialysis in ACLF	60
International collaborative research to improve gallbladder cancer prevention	60
Gut bacteria go on record	60
Nifty new tools for microbiome treatment design	58

A new era in obesity management	57
A neurobiotic sense curbs feeding: a new frontier in gut–brain communication	55
MASLD as a non-communicable disease	54
Nutrient sensing and small intestinal enteric neurons	53
Elucidating the transmission landscape of the human microbiome	52
Pushing the frontier of gut microbiome health cross-kingdom and cross-organ	51
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	50
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	50
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	49
Hepatitis E virus: from innate sensing to adaptive immune responses	48
Tirzepatide to treat obesity: phase III results	47
A novel pathomics signature for gastric cancer	47
Cathepsin S in liver fibrogenesis	46
Microplastics, nanoplastics and liver disease: an emerging health concern?	45
The steatotic liver disease burden paradox: unravelling the key role of alcohol	45
Cellular and molecular basis of proximal small intestine disorders	45
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	44
Antibiotic-perturbed microbiota and the role of probiotics	44
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	43
Classifying compounds as prebiotics — scientific perspectives and recommendations	43
Therapeutic landscape and future direction of metastatic colorectal cancer	43
Commensal fungi in intestinal health and disease	42
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	41
Bridging the gap: increasing MENA representation in MASLD clinical trials	41
Author Correction: Improving IBD outcomes in the era of many treatment options	40
Long-term normothermic liver perfusion	40
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease	39
Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’	39
Author Correction: Current and future colorectal cancer screening strategies	39
Changes in cholera burden across Africa	38
Diet-driven microbiome restoration associated with cardiometabolic benefits	38
Justice, equity, diversity and inclusion in gastroenterology and hepatology	37
Alcohol-free and low-strength drinks: friend or foe?	36
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	36
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	35
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	35
A Roadmap for the Human Gut Cell Atlas	34
Public health policies to prevent alcohol-related liver disease	31
Gut virome dynamics: from commensal to critical player in health and disease	31
ECCO’25	30
Global epidemiology of cirrhosis — aetiology, trends and predictions	30
Resmetirom safe for nonalcoholic fatty liver disease	30
New target and timing in PDAC immunotherapy?	30
Digestive Disease Week 2023	29
Elafibranor in primary biliary cholangitis	29
Envisioning how to advance the MASH field	27
Deciphering potential implications of dietary microplastics for human health	27
Intermittent fasting for NASH and HCC in mice	26
Digestive Disease Week 2025	26
Microplastics and nanoplastics in the human gut: from signals to standards	25
A resource for the food microbiome and its links with the human microbiome	25
Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment	24
Positive longer-term results for efruxifermin in MASH	23
Food inequity and insecurity and MASLD: burden, challenges, and interventions	22
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment	22
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	22
Nanoparticles in NAFLD therapeutics	21
Cholangiocarcinoma 2026: status quo, unmet needs and priorities	21
HCV direct-acting antiviral therapy adherence in people who inject drugs	21
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	21
Optimizing sacral nerve stimulation to relieve chronic constipation	20
Follow-up of SER-109 for recurrent C. difficile	20
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	20
IL-17A-producing CD8+ T cells in pancreatic cancer	20
Human liver tissue in a mouse host	20
Amitriptyline as second-line treatment for IBS in primary care settings	19
Predicting mortality in cirrhosis	19
Gastrointestinal health and the environment: a bidirectional relationship	19
Liquid biopsy combined with machine learning predicts early detection in liver disease	18
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	17
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	17
Lactylation and HCC progression	16
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	16